TACSTD2 and neoplasm: By conjugating a humanized anti-TROP-2 antibody with the topoisomerase I inhibitor SN-38, SG delivers potent cytotoxicity directly to TROP-2-expressing tumor cells, thereby combining targeted specificity with robust anti-tumor activity (22).